

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, March 1, 2016 – Astellas Pharma Inc. (Tokyo : 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced status of the acquisition of its own shares as stated below. The acquisition was implemented pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	16,291,500 shares
3. Aggregate amount of acquisition cost:	26,322,974,095 yen
4. Period of acquisition:	From February 1, 2016 to February 29, 2016
5. Method of acquisition:	Purchased on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on January 29, 2016)

- Class of shares to be acquired:	Common stock of the Company
- Total number of shares to be acquired:	Up to 17 million shares (The percentage compared to the total number of shares outstanding: 0.79%)
- Aggregate amount of acquisition cost:	Up to 30 billion yen
- Period of acquisition:	From February 1, 2016 to March 11, 2016

2. Accumulated Company’s own shares acquired through February 29, 2016, pursuant to the above board resolution

- Total number of shares acquired:	16,291,500 shares
- Aggregate amount of acquisition cost:	26,322,974,095 yen

#####

For inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201, FAX:+81-3-5201-7473

<http://www.astellas.com/en>